ArticleBiomaterials advances2026
Immunomodulatory and pro-mineralizing effects of an injectable baicalein-loaded methacrylated gelatin hydrogel for vital pulp therapy.
Article in Biomaterials advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- More than a trend: the rationale for using bioactive materials in clinical practice.Brazilian oral research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study first investigated the biological function of baicalein (BA) and then developed a photocrosslinkable methacrylated gelatin (GelMA) hydrogel incorporating BA-loaded, carboxylated mesoporous silica nanospheres (MSNs-COOH-BA) for vital pulp therapy. Initially, BA (1-20 μM) was tested for cytocompatibility, in vitro mineralized nodule formation as an early indicator of odontogenic potential, and antioxidant/anti-inflammatory functionality on dental pulp stem cells (DPSCs) and macrophages. Then, 15% (w/v) GelMA was formulated with MSNs-COOH-BA (10 or 20 mg/mL). Hydrogels were characterized by SEM/EDS for their microstructure morphology and chemical composition, as well as for compression, swelling, degradation, and BA release. Biological assessments included DPSC cytocompatibility and early mineralization responses under or without LPS stimulation, macrophage cytokine modulation, and in vivo subcutaneous biocompatibility in rats. Statistical analysis used ANOVA/post-hoc tests (α = 5%). BA was non-cytotoxic (≥70% viability at 24 h), enhanced mineralized nodule formation under both basal and inflammatory conditions, reduced intracellular ROS levels, and suppressed TNF-α, IL-1α, and IL-6 production in a dose-responsive manner. GelMA maintained its porous architecture after MSN incorporation. Although BA-functionalized MSNs showed some nanosphere clustering, they reinforced mechanical performance, with MSNs-COOH-BA (20 mg/mL) increasing Young's modulus and ultimate compressive strength relative to GelMA and outperforming MSNs without BA. MSNs-containing hydrogels displayed moderated swelling and slower enzymatic mass loss versus GelMA alone. BA was released over 10 days, and eluates remained non-cytotoxic (<30% reduction vs control). Under LPS challenge, 20 mg/mL MSNs-COOH-BA induced the highest 21-day mineralized nodule formation in DPSCs, and hydrogel extracts reduced macrophage synthesis of TNF-α and IL-1α. In vivo, all groups exhibited an acute infiltrate at 7 days, which significantly declined by 28 days, with no differences observed among formulations at either time point. The GelMA/MSNs-COOH-BA hydrogel paired sustained BA delivery with mechanical integrity, cytocompatibility, anti-inflammatory activity, and early pro-odontogenic cellular responses, supporting its promise as an injectable biomaterial with clinically relevant therapeutic properties for preserving pulp vitality while supporting the dentin-pulp complex's intrinsic repair and development abilities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.